S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
NASDAQ:ATNX

Athenex Stock Forecast, Price & News

$1.77
-0.01 (-0.56%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.72
$1.85
50-Day Range
$1.77
$3.42
52-Week Range
$1.70
$15.00
Volume
2.38 million shs
Average Volume
2.87 million shs
Market Capitalization
$193.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.59
30 days | 90 days | 365 days | Advanced Chart
Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.


Athenex logo

About Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Headlines

Athenex, Inc. (NASDAQ:ATNX) CEO Buys $10,600.00 in Stock
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATNX
Fax
N/A
Employees
599
Year Founded
N/A

Sales & Book Value

Annual Sales
$144.39 million
Book Value
$1.77 per share

Profitability

Net Income
$-146.18 million
Net Margins
-124.24%
Pretax Margin
-134.95%

Debt

Price-To-Earnings

Miscellaneous

Free Float
93,807,000
Market Cap
$193.49 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

435th out of 1,390 stocks

Pharmaceutical Preparations Industry

202nd out of 669 stocks

Analyst Opinion: 3.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Athenex (NASDAQ:ATNX) Frequently Asked Questions

Is Athenex a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last twelve months. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Athenex stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATNX, but not buy additional shares or sell existing shares.
View analyst ratings for Athenex
or view top-rated stocks.

How has Athenex's stock price been impacted by Coronavirus (COVID-19)?

Athenex's stock was trading at $9.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATNX stock has decreased by 81.7% and is now trading at $1.77.
View which stocks have been most impacted by COVID-19
.

When is Athenex's next earnings date?

Athenex is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Athenex
.

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.08. Athenex had a negative net margin of 124.24% and a negative trailing twelve-month return on equity of 94.71%. During the same period in the prior year, the business earned ($0.44) earnings per share.
View Athenex's earnings history
.

What price target have analysts set for ATNX?

9 equities research analysts have issued 1 year price objectives for Athenex's shares. Their forecasts range from $4.00 to $13.00. On average, they anticipate Athenex's stock price to reach $6.83 in the next twelve months. This suggests a possible upside of 286.1% from the stock's current price.
View analysts' price targets for Athenex
or view top-rated stocks among Wall Street analysts.

Who are Athenex's key executives?

Athenex's management team includes the following people:
  • Yiu Nam Lau, Chairman & Chief Executive Officer
  • Jeffrey M. Yordon, COO & President-Athenex Pharmaceutical Division
  • Steven Adams, Controller, Chief Financial & Accounting Officer
  • Rudolf Kwan, Chief Medical Officer
  • William Zuo, President-China Operations

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

When did Athenex IPO?

(ATNX) raised $72 million in an initial public offering (IPO) on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

Who are Athenex's major shareholders?

Athenex's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.35%), Millennium Management LLC (1.95%), Morgan Stanley (1.41%), Credit Suisse AG (0.81%), Renaissance Technologies LLC (0.53%) and UBS Group AG (0.52%). Company insiders that own Athenex stock include Benson Kwan Hung Tsang, Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan and William Wei Zuo.
View institutional ownership trends for Athenex
.

Which institutional investors are selling Athenex stock?

ATNX stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Morgan Stanley, Deltec Asset Management LLC, Rafferty Asset Management LLC, Squarepoint Ops LLC, Royal Bank of Canada, Voloridge Investment Management LLC, and UBS Group AG.
View insider buying and selling activity for Athenex
or view top insider-selling stocks.

Which institutional investors are buying Athenex stock?

ATNX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Credit Suisse AG, BlackRock Inc., Goldman Sachs Group Inc., Deutsche Bank AG, HighTower Advisors LLC, and Dimensional Fund Advisors LP. Company insiders that have bought Athenex stock in the last two years include Benson Kwan Hung Tsang, Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, and Rudolf Kwan.
View insider buying and selling activity for Athenex
or or view top insider-buying stocks.

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $1.77.

How much money does Athenex make?

Athenex has a market capitalization of $193.49 million and generates $144.39 million in revenue each year. The company earns $-146.18 million in net income (profit) each year or ($1.46) on an earnings per share basis.

How many employees does Athenex have?

Athenex employs 599 workers across the globe.

What is Athenex's official website?

The official website for Athenex is www.athenex.com.

Where are Athenex's headquarters?

Athenex is headquartered at 1001 Main Street Suite 600, Buffalo NY, 14203.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at (716) 427-2950 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.